Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
A Proffered Paper oral presentation will detail results from EFTISARC-NEO, a Phase II investigator-initiated trial in resectable soft tissue sarcoma, and data from the INSIGHT-003 Phase I investigator-initiated trial in first-line non-small cell lung cancer (1L NSCLC) has been accepted for poster presentation. Additionally, an abstract on the Company's pivotal TACTI-004 Phase III in 1L NSCLC has been accepted for a Trials in Progress ePoster. Details of the presentations are as follows:
Title:
EFTISARC-NEO: A phase II study of neoadjuvant eftilagimod alpha, pembrolizumab and radiotherapy in patients with resectable soft tissue sarcoma
Presenter:
Katarzyna Kozak, M.D., Ph.D., Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Session Category:
Proffered Paper
Session Title:
Sarcoma
Presentation #:
2686O
Date and Time:
Sunday, 19 October 2025 at 16:30 – 18:00 PM CET
Title:
Eftilagimod alpha (soluble LAG-3 protein) combined with 1st line chemo-immunotherapy in metastatic non-squamous non-small cell lung cancer (NSCLC) –Updates from INSIGHT-003 (IKF614)
Presenter:
Dr. med. Akin Atmaca, Department of Hematology and Oncology, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany
Session Category:
Poster
Session Title:
NSCLC, metastatic
Presentation #:
1857P
Date and Time:
Saturday, 18 October 2025 at 12:00 – 12:45 PM CET
Title:
TACTI-004, a double-blinded, randomised phase 3 trial of eftilagimod alfa plus pembrolizumab (P) + chemotherapy (C) vs placebo + P + C in 1st line advanced/metastatic NSCLC
Presenter:
Prof. Dr. med. Hans-Georg Kopp, Robert Bosch Hospital, Stuttgart, Germany
Session Category:
ePoster
Session Title:
NSCLC, metastatic
Presentation #:
2086eTiP
Proffered Papers at ESMO are oral presentations of original data of superior quality, followed by expert discussion and perspectives.
Abstracts will be made available on the ESMO website on 13 October 2025 at 00.05 CET. The posters will be available on the Posters & Publications section of Immutep's website after their presentations.
About ImmutepImmutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Australian Investors/Media:Eleanor Pearson, Sodali & Co.+61 2 9066 4071; eleanor.pearson@sodali.com
U.S. Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000; chris.basta@immutep.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Man, 30, suffered gym pain, then doctors asked where he'd like to die
A 29-year-old man, Alex Able, was planning a future family with his wife, Elle, when doctors diagnosed him with one of the world's rarest forms of cancer. It came just two years after his wedding in 2021, when Alex, now 30, residing in Kent with Elle, 27, and their two cats, Socks and Sage first noticed shoulder pain in September 2023. As a regular gym-goer, the couple put the pain down to that and didn't think much of it, but it persisted and kept him awake at night. Read more: State Pension age rising for people born in these years in 2026 This led Alex to undergo an MRI scan in November 2023, but it came back clear. While it was a relief, by May 2024, the pain had worsened, leading to a subsequent scan revealing a large tumour on his shoulder and near his spinal cord. Surgeons succeeded in removing 90% of the mass, leaving 10% due to its proximity to Alex's spine. The tumour was sent for testing, and within a fortnight, a shocking diagnosis was delivered, reports The Mirror. "Our world came crashing down around us all," said Alex's mother-in-law, Katie Bleach, 44, from Kent, who has been speaking to the press on behalf of her daughter, Elle, and son-in-law, Alex. Alex was diagnosed with a Rhabdoid tumour - a vicious and extremely rare form of cancer that predominantly strikes young children. This particular type of illness is so uncommon that Katie revealed there are believed to be approximately 11 confirmed cases across Europe, with Alex thought to be the first instance in the UK. "They [doctors] explained that Rhabdoid tumours behave like spider webs, fine strands that cling to whatever they can grab. Alex's was dangerously close to his spinal cord, attached to muscles and nerves controlling his arm movement," the devastated parent revealed. Four weeks after his initial surgery, the tumour had grown back to its original size. He underwent intense radiotherapy, every day for six weeks, in an attempt to shrink the mass. "The radiotherapy caused burns and inflammation to his throat, and he struggled to eat or drink. He was losing weight rapidly, but he kept pushing through," Katie said. He then went on to have chemotherapy, and despite the odds, "started to build himself back up". At a halfway scan, small tumours appeared in his lungs, lower back, and shoulder bone, but as chemo continued by the end of December, the secondary tumours in his lung had halved in size and the patch in his lower back bone had gone. The original tumour on his shoulder "remained stable," and Alex and Elle started making plans for their future, including an exciting move from Kent to Shropshire. Alex finished chemo in March 2025 and celebrated his 30th birthday in the same month after a challenging few months. Heartbreakingly, at the end of April, Alex became unwell and experienced strange sensations in his legs and pain in his back. In just a few days, his health deteriorated, and further results revealed that the tumours in his lungs had returned. In addition, there were new growths in his lower back, which impacted his mobility, and two small lesions were in his brain. Katie shared: "Over the coming weeks, difficult decisions were made; they pulled out of their dream home, Wills were drawn up, conversations about his declining mobility and future care were had." Alex underwent radiotherapy to his brain and lower spine, and intense physiotherapy to help him walk again. Chemo also resumed, but the morning after the first of his third chemo cycle, Alex woke up and couldn't feel his legs. He had sudden paralysis from his chest down, and an MRI revealed that two new growths were found in his spine, bringing the total to seven tumours. Katie shared that before his diagnosis, Alex and Elle, who have been together since 2019 and got engaged just nine months later, "loved travelling, eating out, going on adventures, went out with friends a lot and were film buffs". She added: "Their hopes for the future were aligned; they were desperate to move to Shropshire, and both wanted to live in the countryside. "They wanted a more outdoorsy life and were thinking of starting a family. Their adventures were only just beginning." On her daughter's reliance, Katie added: "She's the strongest. and the most courageous girls I know. She's been an absolute tower of strength to Alex, giving him nothing but love and encouragement with a constant belief that they're going to come through the other end." Due to the rarity of Alex's diagnosis and it not commonly being seen in adults, receiving treatment has been challenging. On July 11, Alex and his family were hit with the gut-wrenching news that his cancer was "now uncontrollable" and that his treatment was being terminated. Devastated Katie shared: "Despite what they might think is best for Alex, they aren't delivering any actual care; all they're doing is managing his symptoms." She continued: "He's comfortable and well looked after, but his condition in effect is only just getting worse." On Wednesday, 30 July, Katie said they had "the worst day in the last 18 months". She shared: "It was a horrific day. Alex was really uncomfortable; he had hardly any sleep the day before, and he woke up saying he was done. We all gathered around him thinking, he looks so ill, this is it, we've run out of time. "I think part of his feeling so low is that he's fully aware that his cancer is potentially progressing while he's been lying there. He was starting to lose hope." After Alex said he had had enough, Katie said he was offered to go home or to a hospice. "They essentially asked him where he would like to die," she added. Refusing to give up, the family have been researching alternative treatment routes outside of the NHS for the last three weeks and set up a GoFundMe page to help raise costs to cover Alex's treatment moving forward, including travel and any additional costs. After weeks of research and rejections, Katie connected with a Professor in Germany who, despite being unable to treat Alex personally, provided details of seven treatment options, all currently used in Germany's leading Rhabdoid tumour institute - the University Medical Centre, Augsburg. You can visit Alex's GoFundMe page here. Professor Robin Jones of the Royal Marsden has since been in contact to say that he is willing to take on Alex's case privately. They are now waiting for further details on his transfer and what the treatment plan will look like for Alex. "Alex is absolutely over the moon, and he's raring to go again. He's always been so determined and said he's going to be the one success case and hopefully a pioneer for children with this awful disease," his mother-in-law said. "We've gone from the darkest place to now, there's some light at the end of the tunnel. We're feeling hopeful again. We will never give up on Alex because he's so determined to live."
CNN
2 hours ago
- CNN
Meet Australia's new species of giant stick insect
A team of Australian scientists has discovered a new species of giant stick insect, Acrophylla alta, in the tropical forests of northeastern Australia. At nearly 40 cm long and weighing 44 grams, it could be the heaviest insect ever recorded in the country.
Yahoo
3 hours ago
- Yahoo
Canaccord Genuity Initiates 'Buy' on Gold Fields (GFI) with $33 Target
Gold Fields Limited (NYSE:GFI) is one of the best stocks to buy amid gold rally. On July 28, Canaccord Genuity issued a 'Buy' rating as it initiated coverage on Gold Fields; it set the target price at $33. The investment bank cited strong near-term growth prospects for the South Africa-headquartered company. Gold Fields, a top-10 global gold producer operating 10 mines worldwide, is poised for near-term growth driven by expansions at Salares Norte and Gruyere through 2026, alongside ongoing development at Windfall and key assets like St Ives, South Deep, and Tarkwa through 2028. Canaccord Genuity projects notable deleveraging by 2027, which could bolster the company's capacity for M&A and support a re-rating of its shares through rising production, profits, and shareholder returns. Gold Fields Limited (NYSE:GFI) is a globally diversified gold mining company. It explores for, develops, and produces gold, with additional activities in copper and silver extraction. The company operates nine mines across South Africa, Australia, Ghana, Chile, and Peru, and owns the Windfall Project in Québec, Canada. Its primary product is gold bullion, refined from both underground and surface mining operations. While we acknowledge the potential of GFI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
